department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Spevigo · pharmadog

pharmadog
drugs
Spevigo

drug · antibody

patient view →

spesolimab

Marketedupdated 2mo ago

by Boehringer Ingelheim International GmbH🔗 ChEMBL

Approved

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 9 investigational indications.

targets

IL36 receptor

all catalysts(5)

approval · 5

News(0)

no news has mentioned this drug yet

brand

Spevigo

trade names

Spevigo

generic

spesolimab

MOA

IL36 receptor antagonist

indication

Pyoderma Gangrenosum

phase

marketed

SPEVIGO (SPESOLIMAB-SBZO) — FDA approval

SPEVIGO (SPESOLIMAB-SBZO) — FDA approval

SPEVIGO (SPESOLIMAB-SBZO) — FDA approval

SPEVIGO (SPESOLIMAB-SBZO) — FDA approval

SPEVIGO (SPESOLIMAB-SBZO) — FDA approval

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 49m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

drugSPEVIGO20 co-mentions · 5 sources
tagApproval20 co-mentions · 5 sources
companyBoehringer Ingelheim Corp10 co-mentions · 5 sources

Trials studying spesolimab

phase3A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimabterminatedn=39
phase3A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosumrecruitingn=90
phase4A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flaresactive not recruitingn=42
phase2Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Studyactive not recruitingn=131
phase2Spesolimab in Pyoderma Gangrenosumterminatedn=5
—Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasiswithdrawn
phase3A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrometerminatedn=43
phase2A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trialcompletedn=45

more trials →